https://www.selleckchem.com/pr....oducts/Tranilast.htm
Tenofovir amibufenamide (TMF) can provide more efficient delivery than tenofovir disoproxil fumarate (TDF). To compare the efficacy and safety of TMF and TDF for 48 weeks in patients with chronic hepatitis B (CH. We performed a randomised, double-blind, non-inferiority study at 49 sites in China. Patients with CHB were assigned (21) to receive either 25mg TMF or 300mg TDF with matching placebo. The primary efficacy endpoint was the proportion of patients with hepatitis B virus (HBV) DNA less than 20IU/mL at week 48. We also assessed
Like
Comment
Share
